In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 38315998.
- Also identified by DOI 10.7326/J23-0122.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ford AC, Wright-Hughes A, Alderson SL, et al; ATLANTIS trialists. <b>Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.</b> Lancet. 2023;402:1773-1785. 37858323.
Medical subject headings
- Irritable Bowel Syndrome